93 related articles for article (PubMed ID: 1718154)
1. [The effects of mepartricin on the symptomatology of prostatic hypertrophy--double-blind controlled trial].
Vanden Bossche M; Abi Aad A; Vandendris M; Van Cangh P; Schulman C
Acta Urol Belg; 1991; 59(1):93-104. PubMed ID: 1718154
[TBL] [Abstract][Full Text] [Related]
2. [The role of mepartricin in the medical treatment of benign prostatic adenoma].
Casella G; Barbaro A
Arch Sci Med (Torino); 1978; 135(1):95-8. PubMed ID: 76466
[TBL] [Abstract][Full Text] [Related]
3. [Mepartricin 150.000 (40 mg) vs mepartricin 50.000 U (13 mg) in the treatment of BIP. Double blind clinical trial].
Mirone V; Prezioso D; Palmieri A; Lotti T
Minerva Med; 1996 Apr; 87(4):147-54. PubMed ID: 8700338
[TBL] [Abstract][Full Text] [Related]
4. Estrogen suppression as a pharmacotherapeutic strategy in the medical treatment of benign prostatic hyperplasia: evidence for its efficacy from studies with mepartricin.
Boehm S; Nirnberger G; Ferrari P
Wien Klin Wochenschr; 1998 Dec; 110(23):817-23. PubMed ID: 10025034
[TBL] [Abstract][Full Text] [Related]
5. Double-blind, placebo-controlled trial to assess the efficacy and tolerability of mepartricin in the treatment of BPH.
Denis L; Pagano F; Nonis A; Robertson C; Romano P; Boyle P
Prostate; 1998 Dec; 37(4):246-52. PubMed ID: 9831221
[TBL] [Abstract][Full Text] [Related]
6. [Double-blind evaluation of mepartricin 150.000 U (40 mg) compared with placebo in benign prostatic hypertrophy].
Prezioso D; Mirone V; Fabrizio F; Lotti T
Minerva Urol Nefrol; 1996 Dec; 48(4):207-11. PubMed ID: 9005590
[TBL] [Abstract][Full Text] [Related]
7. [The effect of mepartricin on prostatic adenoma].
Pellet B; Granata F; von Niederhäusern W
Rev Med Suisse Romande; 1980 Nov; 100(11):899-903. PubMed ID: 6162182
[No Abstract] [Full Text] [Related]
8. A double-blind placebo-controlled study evaluating the onset of action of doxazosin gastrointestinal therapeutic system in the treatment of benign prostatic hyperplasia.
Roehrborn CG; Prajsner A; Kirby R; Andersen M; Quinn S; Mallen S
Eur Urol; 2005 Sep; 48(3):445-52; discussion 452. PubMed ID: 15996811
[TBL] [Abstract][Full Text] [Related]
9. [Therapeutic efficacy of mepartricin in the medical treatment of prostatic hypertrophy].
Virgili G; Mearini E; Sbarberi L; Camilli P; Costantini E
Minerva Med; 1986 May; 77(20):861-6. PubMed ID: 2425285
[TBL] [Abstract][Full Text] [Related]
10. A multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of terazosin in the treatment of benign prostatic hyperplasia.
Elhilali MM; Ramsey EW; Barkin J; Casey RW; Boake RC; Beland G; Fradet Y; Trachtenberg J; Orovan WL; Schick E; Klotz LH
Urology; 1996 Mar; 47(3):335-42. PubMed ID: 8633398
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of a pelargonium sidoides preparation in patients with the common cold: a randomized, double blind, placebo-controlled clinical trial.
Lizogub VG; Riley DS; Heger M
Explore (NY); 2007; 3(6):573-84. PubMed ID: 18005909
[TBL] [Abstract][Full Text] [Related]
12. [Randomized double-blind study using mepartricin and a placebo in the therapy of benign prostatic hypertrophy].
Miano L; Manieri C; Paradiso Galatioto G
Minerva Urol Nefrol; 1988; 40(2 Suppl):50-2. PubMed ID: 2460952
[No Abstract] [Full Text] [Related]
13. The effect of prazosin on patients with symptoms of benign prostatic hypertrophy.
Steven ID; Coffey GA; Graham NM; Wlodarczyk J; Curtis P
Aust Fam Physician; 1993 Jul; 22(7):1260-4. PubMed ID: 7690542
[TBL] [Abstract][Full Text] [Related]
14. Mepartricin long-term administration regulates steroid hormone and adrenergic receptor concentrations in the prostate of aged rats.
Barbero R; Badino P; Odore R; Galmozzi MR; Cuniberti B; Zanatta R; Re G
J Vet Pharmacol Ther; 2006 Aug; 29(4):289-97. PubMed ID: 16846466
[TBL] [Abstract][Full Text] [Related]
15. A multicentric, placebo-controlled, double-blind clinical trial of beta-sitosterol (phytosterol) for the treatment of benign prostatic hyperplasia. German BPH-Phyto Study group.
Klippel KF; Hiltl DM; Schipp B
Br J Urol; 1997 Sep; 80(3):427-32. PubMed ID: 9313662
[TBL] [Abstract][Full Text] [Related]
16. BXL628, a novel vitamin D3 analog arrests prostate growth in patients with benign prostatic hyperplasia: a randomized clinical trial.
Colli E; Rigatti P; Montorsi F; Artibani W; Petta S; Mondaini N; Scarpa R; Usai P; Olivieri L; Maggi M;
Eur Urol; 2006 Jan; 49(1):82-6. PubMed ID: 16310924
[TBL] [Abstract][Full Text] [Related]
17. Alfuzosin in the treatment of benign prostatic hyperplasia: effects on symptom scores, urinary flow rates and residual volume. A multicentre, double-blind, placebo-controlled trial. ALFECH Study Group.
Hansen BJ; Nordling J; Mensink HJ; Walter S; Meyhoff HH
Scand J Urol Nephrol Suppl; 1994; 157():169-76. PubMed ID: 7524141
[TBL] [Abstract][Full Text] [Related]
18. [Double-blind study on the effects of mepartricin (SPA-S-160) versus placebo in the treatment of obstruction caused by adenoma of the prostate].
Rizzo M; Tosto A; Dattolo E; Serni S
Minerva Urol Nefrol; 1988; 40(2 Suppl):21-2. PubMed ID: 2460940
[No Abstract] [Full Text] [Related]
19. [Mepartricin in BPH. A new dosage approach].
Prezioso D; Fabrizio F; Russo A; Lotti T
Minerva Urol Nefrol; 1996 Jun; 48(2):117-20. PubMed ID: 8815556
[TBL] [Abstract][Full Text] [Related]
20. [Mepartricin as medical treatment of benign prostatic hypertrophy].
Micali F; Giurioli A; Virgili G; Vespasiani G
J Urol (Paris); 1993; 99(6):293-5. PubMed ID: 7516370
[No Abstract] [Full Text] [Related]
[Next] [New Search]
